Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pelareorep in 3rd line HR+/HER2 negative breast cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 04, 2024 9:24pm

206 Views

Post# 36254183

RE:RE:RE:RE:RE:RE:RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer

As reminder regarding the acquisition of an early stage Phase 1 single agent drug candidate - on September 30, 2024 Roche/Genentech announced an US$850 Million up-front cash payment (with future follow-on development milestone payments) for the acquisition of Regor Therapeutics single agent, and single indication small molecule breast cancer product that is in early stage development.

Also Roche/Genetech's acquisition of Rigor's RGT-419B CDK 4 inhibitor is on the basis of only one Phase 1 clinical trial involving 12 patients.

<< Previous

Bullboard Posts

Next >>

How does sponsorship affect share price?